Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment
Journal of Psychiatry and Neuroscience2007Vol. 32(5), pp. 331–338
Citations Over TimeTop 10% of 2007 papers
Ric M. Procyshyn, Kishor M. Wasan, Allen E. Thornton, Alasdair M. Barr, Eric Chen, Edith Pomarol‐Clotet, Émmanuel Stip, Richard L. Williams, G. William MacEwan, C. Laird Birmingham, William G. Honer
Abstract
Elevation of serum lipids is associated with an improvement in schizophrenia symptoms in subjects treated with clozapine. Although the mechanism is unclear, serum lipids may play a role in influencing clozapine's therapeutic activity.
Related Papers
- → How to identify and manage non-response to clozapine?(2019)9 cited
- → Rechallenge of clozapine in a patient with a history of clozapine-induced myocarditis(2020)2 cited
- A study of the stability of plasma clozapine concentration in patents taking clozapine chronically(2007)
- 重度の精神症状のために 6 ヵ月以上の入院を余儀なくされている統合失調症患者に対するclozapineの有用性研究(2020)